Biomarkers for selecting biologic therapies in asthma
Therapeutic Advances in Respiratory Disease · 2026-03 · 20
DOI: 10.1177/17534666261430646 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 11.03.2026. Verfasst von Sergio E Chiarella und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergic Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Biological Therapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Asthma is a heterogeneous chronic respiratory disease driven by diverse inflammatory pathways that vary across patients. The recognition of distinct molecular endotypes has led to the development of targeted biologic therapies that have transformed the management of moderate-to-severe asthma. However, selecting the most appropriate biologic therapy for each patient remains challenging. Health providers often rely on trial-and-error approaches that may delay disease control, increase costs, and expose patients to unnecessary side effects. Biomarkers are key to precision asthma care, as they provide objective measures of underlying disease mechanisms. Established biomarkers such as blood eosinophil count, fractional exhaled nitric oxide, and serum total immunoglobulin E are important for identifying type 2-high asthma. Sputum biomarkers offer direct insight into airway inflammation, but their use is limited by technical complexity and availability across centers. Emerging biomarkers, including proteomic, transcriptomic, metabolomic, and genomic biomarkers, show promise in further refining biologic therapy selection. In addition, digital biomarkers derived from electronic health records, wearable devices, and artificial intelligence-based algorithms offer new opportunities to capture real-world changes in disease and treatment response. Non-medical drivers of health, particularly socioeconomic factors, are increasingly recognized as modifiers of biologic effectiveness and may also be helpful in selecting biologic therapies. This review summarizes the existing evidence on established and emerging biomarkers used to guide biologic therapy selection in asthma. Integrating multiple biomarkers will be essential to improve biological selection, monitor response, and ultimately achieve the goal of remission in asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergic Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
- Division of Allergic Diseases, Mayo Clinic, Rochester, MN, USA.
- Precision Population Science Lab, Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
- Office of Mayo Clinic Health System Research, Mayo Clinic Health System, MN, USA.
ORCID-Profile: Sergio E Chiarella
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Chiarella, S. E., Novoa-Caicedo, I., Pongdee, T., Wi, C. I., & Juhn, Y. J. (2026). Biomarkers for selecting biologic therapies in asthma. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261430646
Vancouver
Chiarella SE, Novoa-Caicedo I, Pongdee T, Wi CI, Juhn YJ. Biomarkers for selecting biologic therapies in asthma. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261430646
BibTeX
@article{Chiarella2026,
author = {Chiarella, Sergio E and Novoa-Caicedo, Isabella and Pongdee, Thanai and Wi, Chung-Il and Juhn, Young J},
title = {Biomarkers for selecting biologic therapies in asthma},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2026},
volume = {20},
doi = {10.1177/17534666261430646}
}
EUVIMED